EUVIMEDEUVIMED entdecken
Leserbrief

RB1 transcript analysis detects novel splicing aberration in retinoblastoma

Kumar Jeyaprakash, Kannan Thirumalairaj, Usha Kim, Veerappan Muthukkaruppan, Ayyasamy Vanniarajan iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30290 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Kumar Jeyaprakash und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Retinoblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: Retinoblastoma (RB) is the most common intraocular neoplasm of progenitor retinal cells caused by biallelic genetic or epigenetic inactivation in retinoblastoma 1 gene (RB1) gene.1 Globally∼9000 newRB cases are reported every year with highest incidence (∼1500 case) in India.2 RB1 gene testing is crucial for genetic counselling and clinical management of RB. Molecular genetic methods such as exon-by-exon (Sanger) sequencing, multiplex ligation-dependent probe amplification (MLPA), and methylation-specific (MS) MLPA are now widely used to determine pathogenic RB1 alterations and combinedly achieve mutation detection rate of 95%–97.1% in tumor tissue.3–5 Unidentified alterations, however, may reside within intronic regions that regulate precursor mRNA splicing and are not usually covered by aforementioned techniques.6 The intronic alterations if pathogenic can cause exon skipping and/or intron retention by creating cryptic or disrupting transcription regulatory splice sites.6 The gene-specific RT-RNA PCR is a cost-effective approach and employed to detect splicing anomalies caused by intronic changes in hereditary diseases including cancers.7,8 In this study,we investigated completeRB1 transcript usingRT-RNA PCR in five RB tumors whose DNA analyses by Sanger sequencing and MLPA did not reveal any pathogenic single nucleotide or copy number variants in exonic and flanking intronic regions. This study was approved by the Institutional Ethics Review Board of Aravind Medical Research Foundation, India (IRB2012020BAS). Written consent from parents of RB patients prior to sample collection was obtained, and all experiments followed the ethical code of Helsinki. These five tumors were obtained fromone bilateral and four unilateral RB patients (three males and two females). The median age of disease presentation was 19 months (ranging from 4 to 36 months). All patients presented with leukocoria but one additionally had strabismus. All unilateral patients were diagnosed with group E and a bilateral patient had group E (OD) andB (OS).Nopatient hada family historyofRB.As apart of treatment, eyes with group E tumors were primarily enucleated. The histological examination showed three tumors with poor differentiation and two withwell-differentiationpattern.Characteristics of theRBpatients are present in Table 1. RB1 RT-RNA PCR was performed as described elsewhere.9 Briefly, total RNA was prepared from clinical (tumor and blood) samples and converted to complementary DNA (cDNA). Primers were utilized to amplify complete RB1mRNA in six overlapping fragments. These fragments were then resolved, purified, and sequenced. Nucleotide BLAST (Basic Local Alignment Search Tool) was used to align the sequences and find deleted or inserted nucleotide sequences. Our transcript analysis identified RB1 splicing anomalies in two tumors (RBRT38T and RBRT99T). In RBRT38T, two ampliconswith shorter sizes (b1:∼509 bp and b2: ∼614 bp) were noted with 19–22F/R primer set on agarose gel electrophoresis. Gel elution, sequencing and BLAST analysis showed band 1 with skipping of exons 21 and 22, and band 2 with skipping of exon 22 (Figure 1A), causing in-frame deletions. Sequencing of RB1 intronic regions also did not show any sequence alteration (data not shown). The same aberration was earlier reported in familial RB due to unknown genetic change.9 In another tumor (RBRT99T), transcript analysis showed an intense and slightly larger amplicon (>900bp). Subsequent sequencing and BLAST analysis revealed insertion of 52 bp from intron 9 (IVS9+532_+584), leading to out-of-frame and premature termination at codon 321. This intron retention was determined to be caused by a variant (c.939+532T>G) in intron 9. This variant was identified in tumor DNA alone and predicted to cause cryptic exon activation (Figure 1B). Besides, other three tumors (RBRT245T, RBRT21T, and RBRT24T) showed no RB1 amplification/expression at the transcript level (data not shown). Splicing is a posttranscriptional process that excises introns and joins exons to form mature mRNA and is regulated by different splicing regulatory sequences such as ESE, ESS, ISE, and ISS. Pathogenic changes in these regions are associated with diverse human pathological conditions including cancers.6 Exon skipping or pseudoexon inclusion as a consequence of RB1 intronic mutations has already been exemplified in retinoblastoma.8,10,11 Dehainault and coworkers through RB1 cDNA analysis described 103 bp intron sequence insertion between exon 23 and 24 due to deep intronic (RB1: IVS231398A>G) mutation in a familial RB.10 In a study by Sameh et al., a change of RB1, c.1814+1307C>G, was found to create a new splice site leading to inclusion of 126 bp intron sequences between exon 18 and 19.11 McEvoy and coworkers using whole genome sequencing reported RB1 complex structural variations in seven RB tumors including three with chromothripsis.12 In the current investigation, three RB tumors had shown no RB1 mRNA expression, suggesting RB1 inactivation by other mechanisms. Further investigation by whole-genome sequencing of these samples may explain the authentic genetic cause of RB1 inactivation. In conclusion, we report defective RB1 splicing in RB tumors, substantiating that RB1 inactivation is largely due to genetic aberrations in RB and also recommend RB1 screening at the transcript level, especially in tumors with no apparent RB1 alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaRetinal NeoplasmsHumansMutationRNA SplicingDNA Mutational AnalysisUbiquitin-Protein LigasesRetinoblastoma Binding Proteins

Substanzen

RB1 protein, humanUbiquitin-Protein LigasesRetinoblastoma Binding Proteins

Autor:innen und Institutionen

  • Department of Molecular Genetics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.
  • Department of Molecular Biology, Aravind Medical Research Foundation, Affiliated to Alagappa University, Karaikudi, Tamil Nadu, India.
  • Department of Orbit, Oculoplasty and Oncology, Aravind Eye Hospital, Madurai, Tamil Nadu, India.
  • Department of Stem Cell Biology and Immunology, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India.

ORCID-Profile: Ayyasamy Vanniarajan

Zitieren

APA

Jeyaprakash, K., Thirumalairaj, K., Kim, U., Muthukkaruppan, V., & Vanniarajan, A. (2023). RB1 transcript analysis detects novel splicing aberration in retinoblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30290

Vancouver

Jeyaprakash K, Thirumalairaj K, Kim U, Muthukkaruppan V, Vanniarajan A. RB1 transcript analysis detects novel splicing aberration in retinoblastoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30290

BibTeX
@article{Jeyaprakash2023,
  author = {Jeyaprakash, Kumar and Thirumalairaj, Kannan and Kim, Usha and Muthukkaruppan, Veerappan and Vanniarajan, Ayyasamy},
  title = {RB1 transcript analysis detects novel splicing aberration in retinoblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30290}
}
Kostenlos starten →